Genmab — November 2016
-
Den positive udvikling fortsætter. IBB pre-market + 0,26 %
-
Den passer da fint her på vores computere, Ipads og telefoner?
-
1240 er modstandsområde. Nu må vi se om denne holder.
-
Igennem i første hug.
-
Igennem 1250
-
-
-- Fremskridt i 2016 og selskabets strategi
-- Produkterne daratumumab (DARZALEX), ofatumumab (Arzerra), tisotumab
vedotin & HuMax-AXL-ADC
-- Genmabs egenudviklede teknologiplatforme DuoBody og HexaBody
-- Den prækliniske pipeline
-- En gennemgang af regnskabstal og kommercielle kompetencer -
Perfekt timing i slipstrømmen på kraftig stigning i NBI.
-
Omsætning + 78.000
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind